Antipsychotic medication and prefrontal cortex activation: A review of neuroimaging findings

European Neuropsychopharmacology

Volumn 22, Issue 6, 2012, Pages 387-400

  Liemburg, Edith J ^a   Knegtering, Henderikus ^a,b,c   Klein, Hans C ^a,b   Kortekaas, Rudie ^a   Aleman, André ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Lentis   (Netherlands)

Author keywords

Antipsychotic agents; Monoamines; Negative symptoms; Neuroimaging; Prefrontal cortex; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUPHENAZINE; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SERTINDOLE; SULPIRIDE; TIOTIXENE;

ATTENTION; BOLD SIGNAL; BRAIN BLOOD FLOW; DRUG ANTAGONISM; EMOTION; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE INTAKE; GLUCOSE METABOLISM; HUMAN; LEARNING; MEDIAL PREFRONTAL CORTEX; MEDLINE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUPERIOR FRONTAL CORTEX; VENTROLATERAL PREFRONTAL CORTEX; VERBAL BEHAVIOR; WORKING MEMORY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; HUMANS; NEUROIMAGING; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 84860460787     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.12.008     Document Type: Review

References (109)

1. Abbott C., Juárez M., White T., Gollub R.L., Pearlson G.D., Bustillo J., Lauriello J., Ho B., Bockholt H.J., Clark V.P., Magnotta V., Calhoun V.D. Antipsychotic dose and diminished neural modulation: a multi-site fMRI study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 35:473-482.
2. Abi-Dargham A., Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry 2005, 20:15-21.
3. Abler B., Erks S., Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacol. 2007, 191:823-833.
4. Advocat C. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain. Essent. Psychopharmacol. 2005, 6:73-90.
5. Aleman A., Kahn R.S. Feelings you can't imagine: towards a cognitive neuroscience of alexithymia. Trends Cogn. Sci. 2005, 9:553-555.
6. Aleman A., Hijman R., De Haan E.H., Kahn R.S. Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 1999, 156:1358-1366.
7. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156:1686-1696.
8. Amargós-Bosch M., López-Gil X., Artigas F., Adell A. Clozapine and olanzapine, but not haloperidol, suppress 5-HT efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int. J. Neuropsychopharmacol. 2006, 9:565-573.
9. Andreasen N.C. Negative symptoms in schizophrenia, definition and reliability. Arch. Gen. Psychiatry 1982, 39:784-788.
10. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol. 1998, 18:63-101.
11. Baldo J.V., Schwartz S., Wilkins D., Dronkers N.F. Role of frontal versus temporal cortex in verbal fluency as revealed by voxel-based lesion symptom mapping. J. Int. Neuropsychol. Soc. 2006, 12:896-900.
12. Barch D.M., Braver T.S., Cohen J.D., Servan-Screiber D. Context processing deficits in schizophrenia. Arch. Gen. Psychiatry 1998, 55:187-188.
13. Barlett E.J., Wolkin A., Brodie J.D., Laska M.A., Wolf A.P., Sanfilipo M. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res. 1999, 40:115-124.
14. Baas D., Aleman A., Kahn R.S. Lateralization of amygdala activation: a systematic review of functional neuroimaging studies. Brain Res. Rev. 2004, 45:96-103.
15. Berthoz S., Artiges E., Van de Moortele P.F., Poline J.B., Rouquette S., Consoli S.M., Martinot J.L. Effect of impaired recognition and expression of emotions on frontocingulate cortices: an fMRI study of men with alexithymia. Am. J. Psychiatry 2002, 159:961-967.
16. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S. Interaction of COMT Val108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with Schizophrenia. Am. J. Psychiatry 2004, 161:1798-1805.
17. Bishara D., Taylor D. Upcoming agents for the treatment of schizophrenia. Drugs 2008, 68:2269-2292.
18. Blasi G., Popolizio T., Taurisano P., Caforio G., Romano R., Di Giorgio A., Sambataro F., Rubino V., Latorre V., Lo Bianco L., Fazio L., Nardinia M., Weinberger D.R., Bertolino A. Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia. Psychiatry Res. 2009, 173:31-38.
19. Buchsbaum M.S., Haznedar N.M., Aronowitz J., Brickman A.M., Newmark R.E., Bloom R., Brand J., Goldstein K.E., Heath D., Starson M., Hazlett E.A. FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophr. Res. 2007, 94:293-305.
20. Buchsbaum M.S., Haznedar N.M., Newmark R.E., Chu K.-W., Dusi N., Entis J.J., Goldstein K.E., Goodman C.R., Gupta A., Hazlett E.A., Ianuzzi J., Torosjan Y., Zhang J., Wolkin A. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophr. Res. 2009, 114:161-171.
21. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., Nash N.R., Olsson R., Davis R.E., Hacksell U., Weiner D.M., Bran M.R. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Ther. 2005, 315:1278-1287.
22. Busatto G.F., Kerwin R.W. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J. Psychopharmacol. 1997, 11:3-12.
23. Bymaster F.P. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol. 1996, 14:87-96.
24. Carter C.S., Perlstein W., Ganguli R., Brar J., Mintun M., Cohen J.D. Functional hypofrontality and working memory dysfunction in schizophrenia. Am. J. Psychiatry 1998, 155:1285-1287.
25. Chen Y.C., Calpern W.R., Brownell A.L., Matthews R.T., Bodganov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., Jenkinks B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 1997, 38:389-398.
26. Chung G., Remington G. Predictors and markers of clozapine response. Psychopharmacol. 2005, 179:317-335.
27. Cohen R.M., Nordahl T.E., Semple W.E., Andreason P., Litman R.E., Pickar D. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Arch. Gen. Psychiatry 1997, 54:481-486.
28. Cohen R.M., Semple W.E., Cross M., Nordahl H.E., Holcomb H.H., Dowling M.S., Pkckar D. The effects of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 1988, 44:1141-1150.
29. Daniel R., Weinberger D., Jones D., Zigun J., Coppola R., Handel S., Bigelow L., Goldberg T., Berman B., Kleinman J. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 1991, 11:1907-1917.
30. Davidson L., Heinrichs R.W. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res. 2003, 15:69-87.
31. Davies M.A., Compton-Toth B.A., Hufeisen S.J., Meltzer H.Y., Roth B.L. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?. Psychoparmacol. 2005, 178:451-460.
32. Davis C.E., Jeste D.V., Eyler L.T. Review of longitudinal functional neuroimaging studies of drug treatments in patients with schizophrenia. Schizophr. Res. 2005, 78:45-60.
33. Egan M., Goldberg T., Bhaskar S., Kolachana S., Callicot J., Mazzanti C., Straub R., Goldman D., Weinberger D. Effect of COMT VAL108/158 Met genotype on frontal lobe function and risk for schizophrenia. PNAS. 2001, 98:6917-6922.
34. Fahim C., Stip E., Mancini-Marïe A., Gendron A., Mensour B., Beauregard M. Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J. Clin. Pharmacol. 2005, 25:367-371.
35. Glahn D.C., Ragland J.D., Abramoff A., Barett J., Laird A.R., Bearden C.E., Velligan D.I. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum. Brain Mapp. 2005, 25:60-69.
36. Gold J.M., Carpenter C., Randolph T.E., Goldberg T.E., Weinberger D.R. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch. Gen. Psychiatry 1997, 54:159-165.
37. Goldman-Rakic P., Selemon L. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 1997, 23:437-458.
38. Gonul A.S., Kula M., Sofuoglu S., Tutus A., Esel E. Tc-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:29-33.
39. Gozzi A., Crestan V., Turrini G., Clemens M., Bifone A. Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit. Psychopharmacol. 2010, 209:37-50.
40. Hazlett E.A., Buchsbaum M.S. Sensorimotor gating deficits and hypofrontality in schizophrenia. Front. Biosci. 2001, 6:1072-1096.
41. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychol. 1998, 1998:426-445.
42. Hill K., Mann L., Laws K.R., Stephenson C.M., Mimmo-Smith I., McKenna P.J. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr. Scand. 2004, 110:243-256.
43. Holcomb H.H., Cascella N.G., Thaker G.K., Medoff D.R., Dannals R.F., Tamminga C.A. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry 1996, 152:41-49.
44. Honey G.D., Bullmore E.T., Soni W., Varatheesan M., Williams S.C., Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Nat. Acade. Sci. USA 1999, 9:13432-13437.
45. Ingvar D.H., Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr. Scand. 1974, 50:425-462.
46. Jansma J.M., Ramsey N.F., van der Wee N.J., Kahn R.S. Working memory capacity in schizophrenia: a parametric fMRI study. Schizophr. Res. 2004, 68:159-171.
47. Jarskog L.F., Miyamoto S., Lieberman J.A. Schizophrenia: new pathological insights and therapies. Annu. Rev. Med. 2007, 58:49-61.
48. Jones H.M., Brammer M.J., O'Toole M., Taylor T., Ohlson R.I., Brown R.G., Purvis R., Williams S., Pilowsky L.S. Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study. Biol. Psychiatry 2004, 56:938-942.
49. Kapur S., McClelland R.A., VanderSpek S.C., Wadenberg M.L., Baker G., Nobrega J., Zipursky R.B., Seeman P. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport 2002, 13:831-835.
50. Kapur S., Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 2001, 158:360-369.
51. Kapur S., Seeman M. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors, implications for atypical antipsychotic action. J. Psychiatry Neurosci. 2006, 25:161-166.
52. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 1999, 156:286-293.
53. Kim D.I., Manoach D.S., Mathalon D.H., Turner J.A., Mannell M., Brown G.G., Ford J.M., Gollub R.L., White T., Wible C., Belger A., Bockholt H.J., Clark V.P., Lauriello J., O'Leary D., Mueller B.A., Lim K.O., Andreasen N., Potkin S.G., Calhoun V.D. Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum. Brain Mapp. 2009, 30:3795-3811.
54. Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., Tamminga C.A. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol. Psychiatry 2003, 53:601-608.
55. Lahti A.C., Holcomb H.H., Weiler M.A., Medoff D.R., Frey K.N., Hardin M., Tamminga C.A. Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacol. 2004, 29:171-178.
56. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Pharmacol. 1994, 55:82-87.
57. Liddle P.F., Pantelis C. Brain imaging in schizophrenia. Schizophrenia 2003, 403-420. Blackwell Science Ltd, Massachusetts. S.R. Hirsch, D.R. Weinberger (Eds.).
58. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004, 18:251-267.
59. McIntosh A.M., Whalley H.C., McKirdy J., Hall J., Sussmann J.E.D., Shankar P., Eve C., Johnstone E.C., Lawrie S.M. Prefrontal function and activation in bipolar disorder and schizophrenia. Am. J. Psychiatry 2008, 165:378-384.
60. Meisenzahl E.M., Scheuerecker J., Zipse M., Ufer S., Wiesmann M., Frodl T., Koutsouleris N., Zetzsche T., Riedel M., Spellman I., Dehning S., Linn J., Brückman H., Möller H.J. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:522-531.
61. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2003, 27:1159-1172.
62. Meltzer H., Lee M., Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr. Scand. 1994, 90:95-101.
63. Mendrek A., Kiehl K.A., Smith A.M., Irwin D., Forster B.B., Liddle P.F. Dysfunction of a distributed neural circuitry in schizophrenia patients during a working-memory performance. Psychol. Med. 2007, 35:187-196.
64. Mendrek A., Laurens K.R., Kiehl K.A., Stip E., Liddle P.F. Changes in distributed neural circuitry function in patients with first-episode schizophrenia. Br. J. Psychiatry 2004, 185:205-214.
65. Miller D.D., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol. Psychiatry 2001, 49:704-715.
66. Molina V., Montz R., Pérez M.J., Capdevila E., Carreras J.L., Rubia F.J. SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. A. J. Psychiatry. 1996, 153:1343-1346.
67. Molina V., Montz R., Pérez M.J., Catalina L.M., Cuesta P., Carreras J.L., Rubia F.J. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res. 1997, 76:51-61.
68. Molina V., Reig S., Sanz J., Pascau J., Santos A. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacol. 2005, 178:17-26.
69. Molina V., Reig S., Sarramea F., Sanz J., Francisco Artaloytia J., Luque R., Aragüés M., Pascau J., Benito C., Palomo T., Desco M. Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia. Psychiatry Res. 2003, 124:153-161.
70. Molina V., Sanz J., Reig S., Martínez R., Sarramea F., Luque R., Benito C., Gispert J.D., Pascau J., Desco M. Hypofrontality in men with first-episode psychosis. Br. J. Psychiatry 2005, 186:203-208.
71. Molina V., Sanz J., Sarramea F., Palomo T. Marked hypofrontality in clozapine-responsive patients. Pharmacopsychiatry 2007, 40:157-162.
72. Molina V., Tamayo P., Montes C., De Luxán A., Martin C., Rivas N. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2008, 32:948-954.
73. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
74. Ngan E.T., Lane C.J., Ruth T.J., Liddle P.F. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change. J. Neurol. Neurosurg. Psychiatry 2002, 72:106-110.
75. Nyberg S., Farde L. The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed. J. Psychopharmacol. 1997, 11:13-14.
76. Onali P., Olianas M.C. N-desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious d-opioid agonist at recombinant and native receptors. Neuropsychopharmacol. 2007, 32:773-785.
77. Parellada E., Catafau M.A., Bernardo M., Lomeña F., Gonzhlez-Monclús E., Setoain J. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatry Res. 2003, 55:131-139.
78. Pehek E. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse 1996, 24:12-18.
79. Perlstein W.M., Carter C.S., Noll D.C., Cohen J.D. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am. J. Psychiatry 2001, 158:1105-1113.
80. Pinkham A.E., Penn D.L., Perkins D.O., Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. Am. J. Psychiatry 2003, 160:815-824.
81. Polli F.E., Barton J.J., Cain M.S., Thakkar K.N., Rauch S.L., Manoach D.S. Rostral and dorsal anterior cingulate cortex make dissociable contributions during antisaccade error commission. Proc. Natl. Acad. Sci. USA 2005, 102:15700-15705.
82. Pomarol-Clotet E., Salvador R., Sarró S., Gomar J., Vila F., Martínez A., Guerrero A., Ortiz-Gil J., Sans-Sansa B., Capdevila A., Cebemanos J.M., McKenna P.J. Failure to deactivate in the prefrontal cortex in schizophrenia: dysfunction of the default-mode network?. Psychol. Med. 2008, 38:1185-1193.
83. Potkin S.G., Buchsbaum M.S., Jin Y., Tang C., Telford J., Friedman G., Lottenberg S., Najafi A., Gulasekaram B., Costa J., Richmond G.H., Bunney W.E. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J. Clin. Psychiatry 1994, 55:63-66.
84. Reimold M. Occupancy of dopamine D(1), D(2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacol. 2007, 190:241-249.
85. Rieheman S., Volz H.P., Stützer P., Smesny S., Gaser C., Sauer H. Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test - a fMRI study. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251:66-71.
86. Röder C.H., Hoogendam J.M., Van der Veen F.M. fMRI, antipsychotics and schizophrenia. Influence of different antipsychotics on BOLD-signal. Curr. Pharm. Des. 2010, 16:2012-2025.
87. Sambataro F., Blasi G., Fazio L., Caforio G., Taurisano P., Romano R., Di Giorgio A., Gelao B., Lo Bianco L., Papazacharias A., Popolizio T., Nardini M., Bertolino A. Treatment with olanzapine is associated with modulation of the default mode network in patients with schizophrenia. Neuropsychopharmacol. 2010, 35:192-904.
88. Schneider F., Habel U., Reske M., Kellerman T., Stöcker T., Shah N.J., Zilles K., Braus D.F., Schmitt A., Schlösser R., Wagner M., Frommann I., Kircher T., Rapp A., Meisenzahl E., Uferi S., Puhrmann S., Thienel R., Sauer H., Henn F.A., Gaebel W. Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study. Schizophrenia Res. 2005, 89:198-210.
89. Schotte A. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol. 1996, 124:57-73.
90. Seeman P. Receptor Tables 1993, SZ Research, Toronto.
91. Sharafi M. Comparison of classical and clozapine treatment on schizophrenia using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT imaging. Int. J. Med. Sci. 2009, 2:79-86.
92. Da Silva Alves F., Figee M., Van Amelsvoort T., Veltman D., De Haan L. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol. Bull. 2008, 41:121-132.
93. Sharafi M. Comparison of classical and clozapine treatment on schizophrenia using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging. Int J. Med. Sci. 2005, 2:79-86.
94. Sipes T.E., Geyer M.A. DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors. Behav. Pharmacol. 1995, 6:839-842.
95. Slagenhauf F., Dinges M., Beck A., Wüstenberg T., Friedel E., Dembler T., Sarkar R., Wrase J., Gallinat J., Juckel G., Heinz A. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophrenia Res. 2010, 118:189-200.
96. Slagenhauf F., Wüstenberg T., Schmack K., Dinges M., Wrase J., Koslowski M., Kienast T., Bauer M., Gallinat J., Juckel G., Heinz A. Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur. Neuropsychopharmacol. 2008, 18:589-599.
97. Soyka M., Koch W., Möller W.J., Rüther T., Tatsch K. Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:308-312.
98. Stip E., Fahim C., Mancini-Marïe A., Bentaleb L.A., Mensour B., Mendrek A., Beauregard M. Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:21-26.
99. Tausscher J., Hussain T., Agid O., Verhoeff P.L.G., Wilson A.A., Houle S., Remington G., Zipursky R.B., Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry 2004, 161:1620-1625.
100. Vaiva G., Thomas P., Llorca P.M., Dupont S., Cottencin O., Devos P., Mazas O., Rascle C., Steinling M., Goudemand M. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res. 2002, 115:37-48.
101. Walter H., Kammerer H., Frasch K., Spitzer M., Abler B. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacol. 2009, 206:121-132.
102. Wang C.S., Yang Y.K., Chen M., Chiu N.T., Yeh T.L., Lee I.H. Negative symptoms and regional cerebral blood flow in patients with schizophrenia: a single photon emission computed tomography study. Kaohsiung J. Med. Science. 2003, 19:464-469.
103. Weinberger D.R., Berman K.F., Illowski B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia; III, a new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry 1988, 45:609-615.
104. Weinberger D.R., Berman K. Prefrontal function in schizophrenia: confounds and controversies. Phylos. Trans. R. Soc. L. B. Biol. Sci. 1996, 351:1495-1503.
105. Weinberger D.R., Faith Berman K.F., Zee R.F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia; I, regional cerebral blood flow evidence. Arch. Gen. Psychiatry 1986, 43:114-124.
106. Wik G., Wiesel F.-A., Sjörgen I., Blomqvist G., Greitz T., Stone-Elander S. Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacol. 1989, 97:309-318.
107. Wittmann M., Marino M.J., Henze D.A., Seabrook G.R., Conn P.J. Clozapine potentiation of N-methyl-d-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J. Pharmacol. Exp. Ther. 2005, 313:594-603.
108. Yildiz A., Eryilmaz M., Gungor F., Erkilic M., Karaylacin B. Regional cerebral blood flow in schizophrenia before and after neuroleptic medication. Nucl. Med. Comm. 2000, 21:1113-1118.
109. Zhao J., He X., Liu Z., Yang D. The effects of clozapine on cognitive function and regional cerebral blood flow in the negative symptom profile schizophrenia. Int. J. Psychiatr. Med. 2006, 36:171-181.